The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 May 2017
At a glance
- Drugs MEDI 3250 (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- 01 May 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2015 Accrual to date is 47% according to United Kingdom Clinical Research Network.
- 25 Oct 2015 Accrual to date is 34% according to United Kingdom Clinical Research Network.